Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

PYZCHIVA

USTEKINUMAB-TTWE

Standard Dose
130MG/26ML(5MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PYZCHIVA is listed in Drugs@FDA under application 761425 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient USTEKINUMAB-TTWE Form and strength INJECTABLE;SUBCUTANEOUS - 130MG/26ML(5MG/ML) Sponsor SAMSUNG BIOEPIS CO LTD Submission history Latest submission status date: 2025-11-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview PYZCHIVA is listed in Drugs@FDA under application 761425 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient USTEKINUMAB-TTWE Form and strength INJECTABLE;SUBCUTANEOUS - 130MG/26ML(5MG/ML) Sponsor SAMSUNG BIOEPIS CO LTD Submission history Latest submission status date: 2025-11-18 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
PYZCHIVA (USTEKINUMAB-TTWE) | Drug Monograph | MedicHelpline